The financial landscape of 2026 is defined by a paradox: machine learning systems are now more powerful and autonomous than ever, yet they operate under the strictest regulatory scrutiny in history.

Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...